Basel, Switzerland

Eric Andre Kusznir

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Eric Andre Kusznir

Introduction

Eric Andre Kusznir is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of medical treatment through his innovative patents. With a total of six patents to his name, Kusznir is recognized for his work in developing compounds that target specific proteins involved in cancer treatment.

Latest Patents

Kusznir's latest patents include groundbreaking inventions such as dihydrobenzimidazolones and dihydroquinolinones for medical treatment. The dihydrobenzimidazolones bind to the E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex. This alteration results in the breakdown of intrinsic downstream proteins, making these compounds useful for cancer treatment. Similarly, the dihydroquinolinones also bind to CRBN and serve a comparable purpose in targeting cancerous cells.

Career Highlights

Kusznir is currently associated with C4 Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in the ongoing fight against cancer, showcasing his commitment to improving medical treatments through innovative solutions.

Collaborations

Some of his notable coworkers include Roger David Norcross and Fabian Dey, who contribute to the collaborative efforts in research and development at C4 Therapeutics, Inc.

Conclusion

Eric Andre Kusznir's contributions to medical treatment through his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in cancer therapy, demonstrating the impact of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…